Since there is no consensus regarding the cutoff value of GPX4 protein expression, we determined negative if less than 5% of tumor cell were stained
Presented for research literature review only Egaas E (2000)
The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
FDA approves new medication for chronic weight management [Internet]
These effects make it an interesting candidate for women seeking to optimize fertility when tissue health is a factor, such as after uterine surgery, like cesarean scar repair, or after pelvic injury that impacts implantation or uterine blood flow
This article will explain the science behind the weekly schedule, the risks of more frequent dosing, and how a personalized program can help you manage your treatment effectively